IGM Biosciences Inc expected to post a loss of 4 cents a share - Earnings Preview

IGM Biosciences

30/07/2024 16:49

* IGM Biosciences Inc  IGMS.OQ   IGMS.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 1
(estimated) for the period ending June 30 2024
    * The Mountain View California-based  company is expected to
report a 12,023.3% increase in revenue to $54.313 million from
$448 thousand a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for IGM Biosciences Inc is
for a
loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for IGM
Biosciences
Inc is $20.00​, above​ its last closing price of $11.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.83       -0.83      -0.83     Met     0.2
 Dec. 31 2024  -0.96       -1.03      -1.01     Beat    2.2
 Jan. 1 0001   -1.18       -1.21      -1.04     Beat    14.3​
 Jun. 30 2023  -1.44       -1.43      -1.43     Met     0.3
 ​​Mar.        -1.34                  -1.33             2.5
 31 2023                                                
 Dec. 31 2022              -1.25      -1.19     Beat    4.5​
 Sep. 30 2022  -1.44       -1.43      -1.32     Beat    7.5
 Jun. 30 2022  -1.27       -0.94      -1.33     Missed  -41.5
 This summary was machine generated July 30 at 15:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)